Andrew M Naidech1, Matthew B Maas2, Kimberly E Levasseur-Franklin2, Eric M Liotta2, James C Guth2, Micheal Berman2, Joshua M Rosenow2, Paul F Lindholm2, Bernard R Bendok2, Shyam Prabhakaran2, Richard A Bernstein2, Hau C Kwaan2. 1. From the Department of Neurology (A.M.N., M.B.M., E.M.L., J.C.G., M.B., S.P., R.A.B.), Department of Neurosurgery (J.M.R., B.R.B.), Department of Pathology (P.F.L.), and Department of Hematology (H.C.K.), Northwestern University, Chicago, IL; and Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL (K.E.L.-F.). a-naidech@northwestern.edu. 2. From the Department of Neurology (A.M.N., M.B.M., E.M.L., J.C.G., M.B., S.P., R.A.B.), Department of Neurosurgery (J.M.R., B.R.B.), Department of Pathology (P.F.L.), and Department of Hematology (H.C.K.), Northwestern University, Chicago, IL; and Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL (K.E.L.-F.).
Abstract
BACKGROUND AND PURPOSE: Minimizing hematoma growth in high-risk patients is an attractive strategy to improve outcomes after intracerebral hemorrhage. We tested the hypothesis that desmopressin (DDAVP), which improves hemostasis through the release of von Willebrand factor, improves platelet activity after intracerebral hemorrhage. METHODS: Patients with reduced platelet activity on point-of-care testing alone (5), known aspirin use alone (1), or both (8) received desmopressin 0.4 μg/kg IV. We measured Platelet Function Analyzer-epinephrine (Siemens AG, Germany) and von Willebrand factor antigen from baseline to 1 hour after infusion start and hematoma volume from the diagnostic to a follow-up computed tomographic scan. RESULTS: We enrolled 14 patients with of mean age 66.8±14.6 years, 11 (85%) of whom were white and 8 (57%) were men. Mean Platelet Function Analyzer-epinephrine results shortened from 192±18 seconds pretreatment to 124±15 seconds (P=0.01) 1 hour later, indicating improved plate activity. von Willebrand factor antigen increased from 242±96% to 289±103% activity (P=0.004), indicating the expected increase in von Willebrand factor. Of 7 (50%) patients who received desmopressin within 12 hours of intracerebral hemorrhage symptom onset, changes in hematoma volume were modest, -0.5 (-1.4 to 8.4) mL and only 2 had hematoma growth. One patient had low blood pressure and another had a new fever within 6 hours of desmopressin administration. CONCLUSIONS: Intravenous desmopressin was well tolerated and improved platelet activity after acute intracerebral hemorrhage. Larger studies are needed to determine its potential effects on reducing hematoma growth versus platelet transfusion or placebo. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00961532.
BACKGROUND AND PURPOSE: Minimizing hematoma growth in high-risk patients is an attractive strategy to improve outcomes after intracerebral hemorrhage. We tested the hypothesis that desmopressin (DDAVP), which improves hemostasis through the release of von Willebrand factor, improves platelet activity after intracerebral hemorrhage. METHODS:Patients with reduced platelet activity on point-of-care testing alone (5), known aspirin use alone (1), or both (8) received desmopressin 0.4 μg/kg IV. We measured Platelet Function Analyzer-epinephrine (Siemens AG, Germany) and von Willebrand factor antigen from baseline to 1 hour after infusion start and hematoma volume from the diagnostic to a follow-up computed tomographic scan. RESULTS: We enrolled 14 patients with of mean age 66.8±14.6 years, 11 (85%) of whom were white and 8 (57%) were men. Mean Platelet Function Analyzer-epinephrine results shortened from 192±18 seconds pretreatment to 124±15 seconds (P=0.01) 1 hour later, indicating improved plate activity. von Willebrand factor antigen increased from 242±96% to 289±103% activity (P=0.004), indicating the expected increase in von Willebrand factor. Of 7 (50%) patients who received desmopressin within 12 hours of intracerebral hemorrhage symptom onset, changes in hematoma volume were modest, -0.5 (-1.4 to 8.4) mL and only 2 had hematoma growth. One patient had low blood pressure and another had a new fever within 6 hours of desmopressin administration. CONCLUSIONS: Intravenous desmopressin was well tolerated and improved platelet activity after acute intracerebral hemorrhage. Larger studies are needed to determine its potential effects on reducing hematoma growth versus platelet transfusion or placebo. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00961532.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Andrew M Naidech; Storm M Liebling; Neil F Rosenberg; Paul F Lindholm; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Hau C Kwaan Journal: Neurocrit Care Date: 2012-02 Impact factor: 3.210
Authors: Pertti Saloheimo; Mikko Ahonen; Seppo Juvela; Juhani Pyhtinen; Eeva-Riitta Savolainen; Matti Hillbom Journal: Stroke Date: 2005-12-01 Impact factor: 7.914
Authors: B B Thompson; Y Béjot; V Caso; J Castillo; H Christensen; M L Flaherty; C Foerch; K Ghandehari; M Giroud; S M Greenberg; H Hallevi; J C Hemphill; P Heuschmann; S Juvela; K Kimura; P K Myint; Y Nagakane; H Naritomi; S Passero; M R Rodríguez-Yáñez; J Roquer; J Rosand; N S Rost; P Saloheimo; V Salomaa; J Sivenius; T Sorimachi; M Togha; K Toyoda; W Turaj; K N Vemmos; C D A Wolfe; D Woo; E E Smith Journal: Neurology Date: 2010-09-08 Impact factor: 9.910
Authors: Koen de Gans; Rob J de Haan; Charles B Majoie; Maria M Koopman; Anneke Brand; Marcel G Dijkgraaf; Marinus Vermeulen; Yvo B Roos Journal: BMC Neurol Date: 2010-03-18 Impact factor: 2.474
Authors: N L Kobrinsky; E D Israels; J M Gerrard; M S Cheang; C M Watson; A J Bishop; M L Schroeder Journal: Lancet Date: 1984-05-26 Impact factor: 79.321
Authors: Rosemarie A Reiter; Florian Mayr; Hannes Blazicek; Elisabeth Galehr; Petra Jilma-Stohlawetz; Hans Domanovits; Bernd Jilma Journal: Blood Date: 2003-08-14 Impact factor: 22.113
Authors: Matthew B Maas; Andrew M Naidech; Minjee Kim; Ayush Batra; Edward M Manno; Farzaneh A Sorond; Shyam Prabhakaran; Eric M Liotta Journal: J Stroke Cerebrovasc Dis Date: 2018-01-05 Impact factor: 2.136
Authors: Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: Lucy Z Kornblith; Anamaria J Robles; Amanda S Conroy; Carolyn M Hendrickson; Carolyn S Calfee; Alexander T Fields; Rachael A Callcut; Mitchell J Cohen Journal: J Trauma Acute Care Surg Date: 2018-11 Impact factor: 3.313
Authors: Elena I Fomchenko; Emily J Gilmore; Charles C Matouk; Jason L Gerrard; Kevin N Sheth Journal: Curr Treat Options Neurol Date: 2018-06-23 Impact factor: 3.598
Authors: Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn Journal: Crit Care Date: 2016-04-12 Impact factor: 9.097